AbbVie, Gedeon Richter to partner on neuropsychiatric drugs –

Or wait…

Preclinical Research
Drug Delivery
Clinical Development
Contract Manufacturing & Logistics
Markets & Regulations
Promotional Features
Site Archive
Hot Topics
Mergers and Acquisitions
Bioavailability Challenge
Patient centricity
Clinical evolution
Transparency on trial
Site Archive
Type of resources
All Events
Editorial Webinars
Related Site
By Jenni Spinner contact
15-Mar-2022 – Last updated on 15-Mar-2022 at 13:43 GMT
Related tags: AbbVie, CNS, Central nervous system, Neurology, Drug discovery, Drug development
function sanitize_gpt_value2(gptValue)
var vOut = “”;
var aTags = gptValue.split(‘,’);
var reg = new RegExp(‘\W+’, “g”);

for (var i=0; i < aTags.length; i++)
vOut += aTags[i].trim().replace(reg, '-').substring(0,40);
if (i!=(aTags.length-1))
vOut +=', ';

vOut = vOut.toLowerCase();
return vOut;

$(document).ready(function() {
dataLayerNews = {};

dataLayerNews.related_tags = sanitize_gpt_value2("AbbVie, CNS, Central nervous system, Neurology, Drug discovery, Drug development");

AbbVie and Gedeon Richter have announced a new co-development and licensing agreement, centered on a joint effort to research, develop, and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.
According to the two companies, this arrangement is built upon results of preclinical research carried out by Richter and includes a number of new chemical entities pinpointed development. AbbVie and Richter have a 15-year history of working together on central nervous system (CNS) projects, including previously globally launched products like cariprazine (VRAYLAR/REAGILA).
Tom Hudson, senior vice president of R&D and chief scientific officer with Abbvie, said in relation to the announcement, “In collaboration with Richter, we will continue to build on our research that seeks to provide additional insights into our understanding of cariprazine’s clinical pharmacology and explore novel chemistry to identify new dopamine receptor modulators. AbbVie is committed to driving progress and finding solutions for patients living with complex neuropsychiatric conditions​.”
I am very pleased to extend our existing co-operation under this new collaboration with AbbVie as it opens the way towards new products that could help alleviate the debilitating psychiatric and cognitive symptoms of many neuropsychiatric conditions, leading to an improved quality of life for patients suffering from these conditions around the world​,” said Gábor Orbán, CEO of Gedeon Richter. “I greatly value AbbVie’s capabilities in the field of development and commercialization of drugs acting on the CNS and we are looking forward to entering this collaboration on new therapeutic options for patients and doctors​.”

Under the terms of the agreement, the collaboration reportedly includes preclinical as well as clinical R&D activities, with financing shared by the two parties. Richter will receive an upfront cash payment, along with potential future development, regulatory, and commercialization milestones; additionally, Richter may also receive sales-based royalties. AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries, and Vietnam.
The transaction is expected to close in the second quarter of 2022; its completion is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.                                                                                                                                           
Copyright – Unless otherwise stated all contents of this web site are © 2022 – William Reed Ltd – All Rights Reserved – Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics: Consolidation, Clinical evolution, Preclinical Research, Clinical Development, Delivery formulations, Preclinical, Delivery technologies, Drug delivery, formulation
Eastern & Western Manufacturing Solutions
Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper
The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from…
Procaps Group Acquires 1st U.S.-Based Softgel Production Facility under the name Sofgen Pharmaceuticals, expanding its iCDMO Business Unit.
Softigel by Procaps | 14-Mar-2022 | Press Release
As a leading pharmaceutical group, Procaps is focused on the expansion of its iCDMO business, offering integrated, end-to-end solutions in innovative softgel…
How Formulation Development Affects Manufacturing
Catalent Pharma Solutions | 24-Feb-2022 | Insight Guide
Due to advances in technology and increased development of parenteral drugs, one of the fastest-growing choices for drug delivery in the pharmaceutical…
Clear Guidelines for IND/CTA
Altasciences | 24-Feb-2022 | Technical / White Paper
There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful…
Show more
Upcoming editorial webinars
On-demand webinars
More promotional features
Sign up to our free newsletter and get the latest news sent direct to your inbox


Add a Comment

Your email address will not be published. Required fields are marked *